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Abstract: Hydrophilic metabolites are closely involved in multiple primary metabolic pathways
and, consequently, play an essential role in the onset and progression of multifactorial human dis-
orders, such as Alzheimer’s disease. This review article provides a comprehensive revision of the
literature published on the use of mass spectrometry-based metabolomics platforms for approach-
ing the central metabolome in Alzheimer’s disease research, including direct mass spectrometry,
gas chromatography-mass spectrometry, hydrophilic interaction liquid chromatography-mass spec-
trometry, and capillary electrophoresis-mass spectrometry. Overall, mounting evidence points to
profound disturbances that affect a multitude of central metabolic pathways, such as the energy-
related metabolism, the urea cycle, the homeostasis of amino acids, fatty acids and nucleotides,
neurotransmission, and others.
Keywords: central metabolites; Alzheimer’s disease; mass spectrometry; central metabolic pathways
1. Alzheimer’s Disease and Metabolomics: The Challenge of Hydrophilic Metabolites
Alzheimer’s disease (AD) is nowadays a major health problem due to the dramatic
population aging worldwide. As this neurodegenerative disorder presents great variability
of complex clinical symptoms and a long pre-symptomatic period, the underlying etiologi-
cal factors remain a tangled meshwork to be unraveled. In this respect, mounting evidence
points to a multifactorial and systemic crosstalk of heterogeneous pathological mechanisms,
encompassing the well-known proteopathies associated with the deposition of β-amyloid
plaques and the hyper-phosphorylation of tau protein, but also other cellular perturba-
tions related to oxidative stress and inflammation, energy-related disturbances, altered
neurotransmission, and metal homeostasis, among others [1–3]. Considering this multi-
faceted nature, numerous authors have extensively explored the potential of metabolomics
for holistically elucidating the characteristic molecular alterations behind the onset and
progression of AD [4,5]. In this vein, nuclear magnetic resonance (NMR) and reversed-
phase liquid chromatography coupled to mass spectrometry (RPLC-MS) are currently
the gold standard techniques in metabolomics, and most of the literature published on
AD research is based on their application to brain, cerebrospinal fluid (CSF), blood, and
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other biological matrices. However, it is recognized that the low sensitivity and low spec-
tral resolution of NMR considerably reduce its coverage, thus impeding comprehensive
metabolomics analysis [6]. On the other hand, although great efforts have been made to
develop large-scale RPLC-MS metabolomics approaches [7], this analytical platform is
usually limited to the determination of low and medium polarity metabolites, such as
lipids (i.e., lipidomics) [8], aromatic amino acids and their microbiota derivatives [9], some
nutrients and food-related metabolites (i.e., nutrimetabolomics) [10,11], and a few other
metabolite classes. Accordingly, the efficient profiling of hydrophilic metabolites is still a
methodological challenge. Hydrophilic metabolites comprise multiple chemical classes,
including sugars, most amino acids and derivatives, biogenic amines, organic acids, and
many others, which are in turn involved in a multitude of central metabolic pathways, such
as the energy-related metabolism (e.g., glycolysis, tricarboxylic (TCA) cycle), the urea cycle,
the one-carbon metabolism, and others. Therefore, orthogonal analytical tools are crucial
to approach this essential piece of the human metabolome puzzle, namely direct mass spec-
trometry (DMS), gas chromatography-mass spectrometry (GC-MS), hydrophilic interaction
liquid chromatography-mass spectrometry (HILIC-MS), and capillary electrophoresis-mass
spectrometry (CE-MS).
DMS fingerprinting, based on the direct introduction of the sample extracts into the mass
spectrometer, shows great utility for high-throughput and comprehensive metabolomics
analysis thanks to the lack of a chromatographic or electrophoretic separation prior to MS de-
tection, which inherently bias the method coverage [12]. However, this screening tool suffers
from considerable ion suppression and the impossibility of resolving isomeric metabo-
lites, which make the use of complementary approaches mandatory. Among MS-based
hyphenated methods, GC-MS has been widely employed in metabolomics because of its
reproducibility, chromatographic resolution, sensitivity, and selectivity [13]. This technique
usually requires the application of a derivatization process before the analysis for increasing
the volatility and thermal stability of metabolites, thus enabling the profiling of numerous low
molecular weight central metabolites, such as amino acids, sugars, organic and fatty acids,
amines, and many other primary metabolites. To avoid this derivatization step, which may
represent an important source of variability and bias, the use of HILIC-MS is significantly
increasing over the last years to analyze hydrophilic metabolites [14]. Complementarily, the
coupling CE-MS provides orthogonal separation performance to LC and GC approaches
for the analysis of highly polar and ionic metabolites [15]. Nonetheless, HILIC and CE
present serious reproducibility-related limitations (e.g., drifts in retention/migration times
along sequence runs) and reduced sensitivity compared with the most robust RPLC-MS and
GC-MS platforms, which consequently hinder their application in large-scale metabolomics.
Although much less employed in metabolomics, other RPLC-based alternatives for approach-
ing polar metabolites include the use of ion-pair agents or derivatization to reduce the
polarity of hydrophilic metabolites. However, ion pairing may provoke ion suppression
during MS analysis, contamination of the MS ion source, and column instability, whereas
common derivatization protocols (e.g., dansylation) are time-consuming and considerably
reduce the method coverage toward specific metabolites classes that are sensitive to the
derivatizing reagent. As a complementary approach, the use of imaging mass spectrometry is
gaining great importance for in situ metabolomics analysis to map the molecular mechanisms
underlying neurodegenerative disorders [16]. These techniques can complement traditional
MS platforms relying on the investigation of postmortem and peripheral biofluid samples,
thus facilitating the association between metabolomics and histological data. However, the
application of these tools in AD research is still scarce and mainly limited to the lipidome [16].
Therefore, considering the inherent limitations of each one of all the platforms usually em-
ployed in metabolomics, more and more authors have emphasized the benefit of combining
complementary techniques to obtain comprehensive metabolomics coverage [17].
The next sections of this review article provide an overview of the literature pub-
lished over the last years aimed to explore the AD-characteristic disturbances in central
metabolites and associated metabolic pathways through the application of the MS-based
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metabolomics platforms that are described above, as summarized in Table 1. The literature
search was conducted in three online databases (Scopus, Web of Science, PubMed), using
the search terms “Alzheimer”, “metabolomics”, “mass spectrometry”, “gas chromatogra-
phy”, “hydrophilic interaction liquid chromatography”, ”capillary electrophoresis”, and
“direct infusion”. Studies not focused on the hydrophilic metabolome were discarded.
Table 1. Summary of hydrophilic-oriented metabolomics studies on Alzheimer’s disease.
Study Population Analytical Platform Biological Sample Key Results (Altered Pathways) Ref.
AD (N = 22)/healthy controls (N = 18) DMS serum
Energy metabolism (glucose, carnitine,





AD (N = 22)/healthy controls (N = 18) DMS serum Phospholipid homeostasis [19]
AD (N = 22)/healthy controls (N = 18) DMS serum
Nitrogen metabolism (guanidine,





AD (N = 19)/healthy controls (N = 17) DMS + RPLC-MS serum Phospholipid homeostasis [21]
AD (N = 30)/healthy controls (N = 30) DMS (APPI) serum
Energy metabolism (creatine, malic
acid), fatty acid metabolism (free fatty






APP × PS1 (N = 30)/WT (N = 30) DMS (ESI+APPI) serum
Energy metabolism (glucose, carnitine,
creatine), fatty acid metabolism (free
fatty acids, eicosanoids), nitrogen
metabolism (urea), amino acid
metabolism, lipid homeostasis
[23]
APP × PS1 (N = 10)/WT (N = 10) DMS urine Unidentified discriminant signals [24]




Energy metabolism (pyruvic acid),









APP × PS1 (N = 30)/WT (N = 30) DMS liver, kidney, spleen,thymus
Energy metabolism (glycolysis, TCA,




polyamines), amino acid metabolism,
lipid homeostasis
[26]
APP × PS1 × IL4-KO (N = 7)/APP ×
PS1 (N = 7)/WT (N = 7) DMS serum
Fatty acid metabolism (eicosanoids),





CRND8 (N = 6)/WT (N = 6) DMS hippocampus




CRND8 (N = 6)/WT (N = 6) DMS cerebellum
Fatty acid metabolism (eicosanoids),
amino acid metabolism, nucleotide
metabolism (purines)
[29]









pentose phosphate, TCA), nucleotide
metabolism, nitrogen metabolism
(urea), amino acid metabolism
[30]
SAMP8 (N = 5, 2 months; N = 6, 7
months; N = 7, 12 months) GC-MS hippocampus
Energy metabolism (TCA, lactic acid),
nitrogen metabolism (urea), amino
acid metabolism, lipid homeostasis
[31]
APP × PS1 (N = 12)/WT (N = 11) GC-MS hippocampus
Energy metabolism (ketone bodies),
amino acid metabolism, sphingolipid
homeostasis
[32]
TASTPM (N = 16)/WT (N = 5) GC-MS whole brain, plasma
Energy metabolism (glycolysis,
pentose phosphate), amino acid
metabolism, steroid homeostasis
[33]
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Table 1. Cont.
Study Population Analytical Platform Biological Sample Key Results (Altered Pathways) Ref.
AD (N = 23)/healthy controls (N = 21) GC-MS serum
Energy metabolism (glucose, TCA,
lactic acid), fatty acid metabolism (free
fatty acids), nucleotide metabolism,
nitrogen metabolism (urea, ornithine),
amino acid metabolism
[34]
AD (N = 24)/MCI (N = 16)/PD (N =
22)/healthy controls (N = 8) GC-MS exhaled breath Phenol (PD) [35]
APPTg2576 (N = 15)/CRND8 (N = 9)/
APPV717I (N = 10)/WT (N = 17 + 9 +
12)
GC-MS urine Urinary odorants [36]
AD (N = 47)/MCI (N = 143)/healthy






AD (N = 57)/MCI (N = 58)/healthy
controls (N = 57) GC-MS + RPLC-MS plasma
Fatty acid metabolism (free fatty
acids), energy metabolism (glycolysis,




DS-AD (N = 78)/DS-control (N = 68) GC-MS + RPLC-MS plasma Energy metabolism (anaerobicrespiration) [39]
APPTg2576 (N = 3)/PS1 (N = 3)/APP ×
PS1 (N = 6)/WT (N = 6)
GC-MS + RPLC-MS hippocampus
Energy metabolism (glycolysis, TCA),
nucleotide metabolism, amino acid
metabolism, neurotransmission
[40]





AD (N = 40)/healthy controls (N = 38) GC-MS + RPLC-MS CSF Two unidentified discriminant signals [42]
APP × PS1 (N = 30)/WT (N = 30) GC-MS + RPLC-MS serum
Energy metabolism (glycolysis, TCA),
fatty acid metabolism (free fatty acids,
fatty acid amides, acyl-carnitines,
eicosanoids), nitrogen metabolism
(urea, citrulline), nucleotide










Energy metabolism (glycolysis, TCA),





APP × PS1 (N = 30)/WT (N = 30) GC-MS + RPLC-MS liver, kidney
Energy metabolism (glycolysis, TCA),
fatty acid metabolism (free fatty acids,
acyl-carnitines), nitrogen metabolism





APP × PS1 (N = 30)/WT (N = 30) GC-MS + RPLC-MS spleen, thymus
Energy metabolism (glycolysis, TCA),
fatty acid metabolism (free fatty acids,
acyl-carnitines), nitrogen metabolism
(urea, putrescine), nucleotide




AD (N = 15)/healthy controls (N = 15) HILIC-MS neocortex 76 unidentified discriminant signals [47]
AD (N =20)/healthy controls (N = 20) HILIC-MS plasma 54 unidentified discriminant signals [48]
MCI_AD (N = 19)/MCI (N =
16)/healthy controls (N = 37) HILIC-MS plasma
Polyamine metabolism, L-arginine
metabolism [49]
CRND8 (N = 18/12, 12/18
weeks)/WT (N = 12/12, 12/18 weeks) HILIC-MS urine




AD (N = 15)/MCI (N = 15)/healthy
controls (N = 15) HILIC-MS + RPLC-MS plasma, CSF
Energy metabolism (glycolysis, TCA),




AD (N = 21)/MCI_AD (N =
12)/MCI_stable (N = 21)/healthy
controls (N = 21)
HILIC-MS + RPLC-MS CSF Nucleotide metabolism, amino acidmetabolism, neurotransmission [52]
AD (N = 9)/healthy controls (N = 9) HILIC-MS + RPLC-MS superior temporalcortex
Amino acid metabolism,
neurotransmission [53]
AD (N = 21)/healthy controls (N = 19) HILIC-MS + RPLC-MS frontal cortex
Amino acid metabolism, purine




AD (N = 30)/MCI (N = 30)/healthy
controls (N = 30) HILIC-MS + RPLC-MS plasma Sphingolipid metabolism [55]
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Table 1. Cont.
Study Population Analytical Platform Biological Sample Key Results (Altered Pathways) Ref.
AD (N = 23)/MCI_AD (N =
9)/MCI_stable (N = 22)/SCI (N = 19) CE-MS CSF
Amino acid metabolism, fatty acid
metabolism, one-carbon metabolism [56]
AD (N = 42)/MCI (N = 14)/healthy
controls (N = 37) CE-MS serum
Amino acid metabolism, fatty acid
metabolism, one-carbon metabolism [57]
AD (N = 17)/asymptomatic AD (N =









AD (N = 3)/FTLD (N = 4)/LBD (N =
3)/healthy controls (N = 9) CE-MS serum, saliva
Energy metabolism, amino acid
metabolism [59]
AD (N = 81)/iNPH (N = 57) CE-MS CSF Energy metabolism, amino acidmetabolism [60]
AD (N = 15)/healthy controls (N = 15) RPLC-MS (ion pairing) CSF Neurotransmission, nucleotidemetabolism, antioxidant defense [61]
AD (N= 40)/MCI (N = 36)/healthy
controls (N = 38) RPLC-MS (ion pairing) CSF
Neurotransmission, nucleotide
metabolism, antioxidant defense [62]
MCI (N = 20)/healthy controls (N =
20)
RPLC-MS
(derivatization) saliva Taurine [63]
CRND8 (N = 12)/WT (N = 12) RPLC-MS(derivatization) urine Taurine, amino acid metabolism [64]
AD_younger (N = 4)/AD_older (N =
4)/healthy controls (N = 3)
RPLC-MS
(derivatization) frontal lobe L-phenylalanine, L-lactate [65]




CSF 53 unidentified discriminant signals [66]
AD I-II (N = 7)/AD III-IV (N = 4)/AD




entorhinal cortex Nucleotide metabolism [67]
2. Alzheimer’s Disease and DMS-Based Metabolomics
DMS analysis has been repeatedly applied in various AD metabolomics studies as a
first-pass screening tool for simultaneously measuring a wide range of metabolite classes,
including hydrophilic metabolites and lipids, in a high-throughput manner [68]. Two-
step extraction of serum samples from AD patients and subsequent DMS fingerprinting
revealed significant perturbations in the circulating levels of energy-related metabolites
(e.g., glucose, fatty acids, and carnitine involved in β-oxidation) and neurotransmitters
(e.g., dopamine) [18]. Additionally, it also found an abnormal phospholipid homeostasis
reflected in reduced levels of species containing polyunsaturated fatty acids, increased
levels of phospholipids composed of saturated fatty acids, and increased content of break-
down products (e.g., choline). Interestingly, this was then corroborated in other DMS-based
works focused on the serum AD-related lipidome [19,20] and phospholipidome [21]. Al-
though the electrospray (ESI) source is the most common ionization technique employed in
DMS analysis, the atmospheric pressure photoionization (APPI) source has demonstrated
complementary performance and metabolomics coverage [22]. In this work, the authors
reported an accumulation of diacylglycerols, free fatty acids, and ceramides in AD serum,
which is in line with the upregulated degradation of membrane lipids that was hypothe-
sized in previous DMS studies, as well as other disturbances related to the monoaminergic
neurotransmission and the urea cycle. These DMS-based high-throughput metabolomics
platforms have also been employed to investigate the AD-like pathology in the APP × PS1
transgenic mouse model by considering multiple biological matrices, namely serum [23],
urine [24], brain [25], and other peripheral organs [26]. The analysis of serum samples
evidenced comparable metabolic disturbances to those reported in human studies, thus
corroborating the utility of this transgenic line to model AD [23]. A similar strategy was
applied to investigate the effect of interleukin-4 depletion (i.e., IL4-KO) on AD pathology
by using APP × PS1×IL4-KO mice [27]. The results showed reduced serum content of
various amino acids and metabolites implicated in the urea cycle, and the accumulation
of eicosanoids in the IL4-KO model, which supported the close link between AD and
inflammatory processes. Metabolomics fingerprinting of brain tissue enabled the in situ
and region-specific investigation of the neuropathological processes underlying this neu-
rodegenerative disorder [25]. Hippocampus and cortex were characterized by profound
alterations in the levels of numerous lipids (e.g., phospholipids, fatty acids, acyl-carnitines,
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steroids) and hydrophilic metabolites (e.g., amino acids and derivatives), whereas other
brain areas such as the cerebellum and olfactory bulbs were less affected. Complementar-
ily, other peripheral organs, including the liver, kidneys, spleen, and thymus, were also
studied to evaluate the systemic manifestations of the molecular mechanisms behind the
AD pathology [26]. In this line, Lin et al. applied DMS metabolomics to characterize the
metabolic perturbations in hippocampus [28] and cerebellum [29] of the CRND8 transgenic
mouse. Interestingly, the most important findings were related to an altered metabolism of
arachidonic acid and eicosanoids, amino acids, nucleotides, and other metabolite classes,
which were in great agreement with the studies performed on the APP × PS1 model.
3. Alzheimer’s Disease and GC-MS Based Metabolomics
Metabolomics based on GC-MS has been successfully applied to various biological
samples for investigating the impact of AD on primary metabolic pathways. Widespread
disturbances related to the glucose metabolism, the urea cycle, and amino acid homeostasis
were detected in seven brain regions from AD patients (hippocampus, entorhinal cortex,
middle-temporal gyrus, cingulate gyrus, sensory cortex, motor cortex, cerebellum), includ-
ing some regions traditionally considered not to be affected [30]. Similar alterations were
observed in the hippocampus of the SAMP8 mouse along a 10-month follow-up, compris-
ing energy-related metabolites, amino acids, lipids, and some others [31]. In this regard,
Han et al. have demonstrated that these hippocampal metabolic perturbations may be
sharpened by chronic unpredictable mild stress in APP × PS1 mice, particularly in relation
to the metabolism of amino acids, ketone bodies, and sphingolipids [32]. Furthermore,
comparative analysis of brain and plasma from TASTPM mice revealed the occurrence of
similar disturbances in both biological matrices, thus reinforcing the utility of peripheral
blood to mirror the neuropathological changes underlying AD [33]. In another study, these
systemic manifestations on the AD-related metabolome were reflected in altered levels of
23 metabolites in serum from AD patients, indicating impaired neurotransmission, energy
metabolism (e.g., TCA cycle), urea cycle, and some others [34]. Finally, other samples ana-
lyzed by GC-MS in AD metabolomics research included exhaled breath [35] and urine [36],
with the aim of investigating the involvement of volatile compounds and odorants in
its etiology.
The combination of GC-MS with RPLC-MS is nowadays one of the most common
strategies to achieve comprehensive metabolomics analysis. This multiplatform was ap-
plied to serum samples from a prospective study among AD, mild cognitive impairment
(MCI), and healthy subjects, uncovering profound lipidomics changes in AD patients at
baseline and increased 2,4-dihydroxybutanoic acid along disease progression [37]. Wang
et al. found that plasma metabolites measured through GC+RPLC-MS might serve to
differentiate AD and amnesic MCI patients from control subjects [38]. The metabolic
signatures associated with AD and MCI shared many metabolites participating in the
metabolism of fatty acids, amino acids, nucleic acids, and one-carbon metabolism, thus
suggesting the occurrence of common pathogenic mechanisms in both dementia disorders.
In a more recent study, plasma metabolomics revealed that AD among the Down syndrome
population is characterized by a shift in energy metabolism toward the upregulation of the
anaerobic respiration [39]. In this line, it has been reported that mitochondrial stress and
altered energy metabolism are major hippocampal disturbances occurring in three trans-
genic models of AD [40]. Metabolomics analysis of CSF has also been proposed to identify
potential biomarkers for an improved diagnostic performance of AD. Czech et al. described
that the combination of cortisol, cysteine, and uridine levels together with other amino
acids yields predictive models with sensitivity and specificity above 80% [41]. Another
study detected two CSF metabolic features with higher discrimination performance than
that provided by traditional amyloid and tau biomarkers, but further confirmatory studies
are needed [42]. To complement the DMS screening analyses that have been described in
the previous section of this review article [18–27], González-Domínguez et al. conducted
a comprehensive metabolomics characterization of the APP × PS1 model by applying
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combined GC-MS and RPLC-MS analysis to serum samples [43], various brain regions [44],
metabolically active organs (i.e., liver, kidney) [45], and organs involved in the immune
function (i.e., spleen, thymus) [46]. These studies validated most of the findings unveiled by
DMS-based metabolomics fingerprinting with regard to the altered homeostasis of lipids
(e.g., phospholipids, sphingolipids, cholesterol, fatty acids and acyl-carnitines), amino
acids, nucleic acids, energy-related metabolism, and many others, both at the central and
the systemic levels.
4. Alzheimer’s Disease and HILIC-MS-Based Metabolomics
Although its use is not as widespread as other metabolomics platforms such as RPLC-
MS and GC-MS, various published works have explored the potential of HILIC-MS to
investigate the AD-related polar metabolome. Two preliminary studies demonstrated
that the statistical modeling of HILIC-MS metabolomics data may provide satisfactory
subject classification by using both brain [47] and plasma [48] samples, but the metabolites
responsible for this discrimination were not identified. In another prospective study, the
analysis of plasma samples from MCI patients, MCI patients who developed AD upon
the follow-up and healthy controls revealed disturbances in 22 metabolic pathways, some
of them traditionally associated with the pathogenesis of AD (e.g., metabolism of choles-
terol, glucose, and amino acids), but also in relation to the polyamine and the L-arginine
metabolism [49]. Recently, urinary metabolomics also highlighted the pivotal involvement
of aromatic amino acids in the CRND8 mouse model, encompassing alterations in the
tryptophan metabolism (e.g., upregulation of the serotonin pathway, downregulation of the
kynurenine pathway), deficient aromatic L-amino acid decarboxylase activity (e.g., accumu-
lation of N-acetylvanilalanine and 3-methoxytyrosine), and changes in microbiota-related
and glycine conjugation processes [50].
Orthogonal RPLC and HILIC separations have also been used in combination to maxi-
mize the metabolomics coverage, as previously described for the RPLC+GC multiplatform.
Trushina et al. accomplished a comprehensive investigation of the metabolic mechanisms
behind the onset of AD and MCI by analyzing plasma and CSF samples, which revealed
alterations in multiple pathways associated with energy metabolism, mitochondrial func-
tion, neurotransmission, amino acid and lipid metabolism, and many others [51]. A similar
analytical approach was employed to predict the progression of AD along four diagnostic
groups, namely healthy control subjects, stable MCI patients, MCI subjects who developed
AD after a 2-year follow-up, and AD patients, which indicated significant alterations in
the CSF levels of some amino acids and taurine-related metabolites [52]. Comparable
findings have been obtained from brain metabolomics profiling, thus suggesting that mod-
ulating the metabolism of amino acids could be a possible therapeutic approach against
AD [53]. Additionally, in the brain, Paglia et al. found profound cortical perturbations in
the metabolism of glycerophospholipids and six central metabolic pathways, of which a
significant impairment of the mitochondrial aspartate metabolism was noteworthy [54].
Conversely, other authors were surprisingly not able to differentiate AD patients and
healthy controls by using combined RPLC+HILIC-MS plasma metabolomics, but a clear
discrimination was achieved between MCI and control subjects [55].
5. Alzheimer’s Disease and CE-MS Based Metabolomics
The application of CE-MS based metabolomics in AD research has only been reported
in five studies published up to date. Ibáñez et al. identified a panel of CSF polar metabolites
that was able to differentiate among subjects with different cognitive status, including
patients with subjective cognitive impairment (SCI), MCI patients that remained stable
within 2 years, MCI patients that progressed to AD after this follow-up period, and AD
patients [56]. In another cohort, the analysis of serum samples evidenced similar alterations
in metabolites related to oxidative stress, deficiencies in energy metabolism, and vascular
risk factors [57]. Furthermore, the authors also found increased serum levels of proline
betaine in AD patients, which is a marker of citrus consumption that has been recently
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validated in a prospective study on cognitive decline [69]. In this line, the analysis of
brain tissue demonstrated that AD pathogenesis could be associated with dysregulated
transmethylation and polyamine metabolism, abnormalities in neurotransmission, and
impaired urea cycle and glutathione synthesis [58]. The two other studies published on CE-
based metabolomics focused on the comparison of various neurodegenerative disorders.
Tsuruoka et al. identified six serum metabolites and two saliva metabolites that were
significantly altered in dementia patients (AD, frontotemporal lobe dementia, and Lewy
body disease), whereas 45 metabolites detected in serum could differentiate at least one
pair of these dementia groups [59]. More recently, the same methodology was employed
to discriminate between AD and idiopathic normal pressure hydrocephalus patients by
analyzing CSF [60].
6. Alzheimer’s Disease and Other RPLC-MS Based Platforms to Explore Central Metabolites
As previously described, there are different strategies to reduce the polarity of hy-
drophilic metabolites for enabling their analysis by means of RPLC-MS. For instance,
Kaddurah-Daouk et al. published various metabolomics studies based on ion pairing and
subsequent electrochemical array detection for studying the involvement of redox-active
CSF metabolites on AD and MCI [61,62]. Alternatively, dansylation has also been em-
ployed as a derivatization procedure for enhancing the resolving power of RPLC for the
analysis of AD-related central metabolites in saliva [63] and urine [64] samples. In this
regard, Takayama et al. developed an alternative approach for chiral metabolomics by
using optically active derivatization reagents, which enabled determining chiral amines
and carboxyls in brain samples as biomarker candidates for AD diagnosis [65]. To conclude,
it should also be noted that various manufacturers have developed novel RPLC stationary
phases with an improved retention of hydrophilic compounds, which have been success-
fully employed for analyzing cationic metabolites in CSF [66] and purine metabolites in
brain [67] of AD patients.
7. Overview on the Involvement of Central Metabolic Pathways in Alzheimer’s Disease
As shown in Table 1, hydrophilic-oriented MS-based metabolomics has demonstrated
significant alterations in the levels of numerous polar metabolites in various biological
matrices (e.g., serum/plasma, CSF, brain) and, consequently, the involvement of central
metabolic pathways in the pathogenesis of AD (Figure 1). One of the most consistent
findings across the metabolomics studies that have been reviewed here is the impairment
of the energy-related metabolism. Altered glucose levels have been repeatedly reported
in both the central nervous system and the peripheral system, suggesting an abnormal
metabolic rate of carbohydrates, which are the main energy source in the brain. In turn,
this was normally accompanied by perturbations in other metabolites participating in
the glycolysis, the pentose phosphate pathway, ketogenesis and gluconeogenesis, the
tricarboxylic (TCA) cycle, β-oxidation of fatty acids, and others (Table 1), thus evidencing
profound disturbances affecting the entire energy metabolic system. Amino acids are
involved in multiple central metabolic pathways, many of which have also been associated
to the onset and progression of AD. It is noteworthy that failures in the homeostasis
of aromatic amino acids and the synthesis of neurotransmitters (e.g., dopamine from
tyrosine, serotonin from tryptophan) have been consistently reported in the literature.
In this respect, growing evidence supports a role of branched chain amino acids in AD
pathogenesis because these can compete with aromatic amino acids for entry into the
brain but also due to their crucial involvement in the modulation of insulin resistance and
energy metabolism. Moreover, various amino acids (e.g., arginine, glutamate/glutamine
system) are closely linked to the nitrogen metabolism through the urea cycle and the
polyamine system, which may also play a major role in brain health (e.g., hyperammonemia-
induced neurotoxicity). Oxidative stress is another pivotal hallmark of AD with great
impact on the metabolome, inducing the reduction of cerebral and circulating levels of
numerous antioxidant metabolites (e.g., glutathione) and the accumulation of by-products
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derived from the oxidative damage to nucleic acids, proteins, and lipids. In this vein,
various authors have reported important deregulations in the metabolism of purines
and pyrimidines, which could be allocated not only to oxidative/nitrosative damage to
nucleic acids but also to energy metabolism failures and impaired cellular signaling. In the
crosstalk of many of the metabolic processes described above, including the homeostasis of
amino acids, the synthesis of purines and redox defense, the one-carbon metabolism is also
considered an essential piece of the AD pathology puzzle, in which hyperhomocysteinemia
is one of the most important risk factors for cognitive decline and dementia. Altogether,
the application of complementary metabolomics platforms for characterizing the polar
metabolome stands out as a powerful strategy to decipher the molecular events behind the
multifactorial pathogenesis and progression of AD.
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8. Conclusions
Hydrophilic metabolites play an essential role in the central and primary pathways of
the human metabolism (e.g., metabolism of carbohydrates, amino acids, and fatty acids).
To approach this pivotal portion of the human metabolome, the coupling of mass spectrom-
etry with gas chromatography (GC-MS), hydrophilic interaction liquid chromatography
(HILIC-MS), and capillary electrophoresis (CE-MS) are currently the analytical techniques
most commonly employed, together with direct mass spectrometry (DMS) analysis for
comprehensive and high-throughput metabolomics. DMS can be regarded as a first-pass
screening tool for rapid and simple metabolomics fingerprinting, but it usually requires
being complemented with other hyphenated MS approaches to overcome its inherent
analytical limitations (e.g., the impossibility of resolving isomeric metabolites, ion sup-
pression) in order to get a deeper insight into the polar metabolome. In this respect, the
coupling GC-MS is the most commonly used platform for profiling low molecular weight
hydrophilic metabolites because of its sensitivity and reproducibility, despite the need for
a derivatization step prior to analysis. As an alternative, HILIC and CE provide orthogonal
separation performance for polar and ionic metabolites, but significant technical develop-
ments are still needed for increasing their robustness and high-throughput capacity. The
application of these metabolomics platforms has demonstrated the great impact of the
onset and progression of AD on central metabolites and associated metabolic pathways,
encompassing disturbances in the energy-related metabolism (e.g., glycolysis, TCA cycle),
nitrogen metabolism (e.g., urea cycle, polyamine metabolism), fatty acid metabolism (e.g.,
β-oxidation, eicosanoids), neurotransmission (e.g., serotonergic, dopaminergic), home-
ostasis of amino acids and nucleotides, and some others. These findings are of utmost
importance for comprehensively understanding the pathogenesis of this neurodegenerative
Biomedicines 2021, 9, 298 10 of 13
disorder with the aim of developing possible therapeutic and preventive approaches and
for discovering potential diagnostic targets. However, it should be noted that unsatisfac-
tory validation studies have been repeatedly reported in AD metabolomics [70–72]. These
inconsistencies can in part arise from analytical issues related to the lack of proper stan-
dardization in metabolomics research but also to the enormous intra- and inter-individual
variability of the human metabolome. Therefore, many authors have emphasized in recent
years the great potential of metabolomics to comprehensively investigate biological path-
ways and the etiopathology of diseases but also the extreme difficulty of using metabolites
as robust biomarkers for diagnosis/prognosis in the clinical practice [73].
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